Publications scientifiques

Depuis le 16/07/2024
  1. Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life.
    Taillé C, Humbert M, Bourdin A, Thonnelier C, Lajoinie A, Chassetuillier J, Molimard M, Deschildre A.
    ERJ Open Res. 2024
  2. Reader Response: Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study.
    Khouri C, Pariente A.
    Neurology. 2024
  3. Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic.
    Cracowski JL, Molimard M, Richard V, Roustit M, Khouri C.
    Expert Opin Drug Saf. 2024
  4. Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase.
    Maillard O, Bun R, Laanani M, Verga-Gérard A, Leroy T, Gault N, Estellat C, Noize P, Kaguelidou F, Sommet A, Lapeyre-Mestre M, Fourrier-Réglat A, Weill A, Quantin C, Tubach F.
    Therapie. 2024
  5. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study.
    Guillot J, Justice AC, Gordon KS, Skanderson M, Pariente A, Bezin J, Rentsch CT.
    J Gen Intern Med. 2024
  6. Tyrosine Kinase Inhibitors in Cancers: Treatment optimization - Part II.
    Ferrer F, Tetu P, Dousset L, Lebbe C, Ciccolini J, Combarel D, Meyer N, Paci A, Bouchet S.
    Crit Rev Oncol Hematol. 2024
  7. Tyrosine Kinase Inhibitors in Cancers: treatment optimization - Part I.
    Combarel D, Dousset L, Bouchet S, Ferrer F, Tetu P, Lebbe C, Ciccolini J, Meyer N, Paci A.
    Crit Rev Oncol Hematol. 2024
  8. Can requests for real-world evidence by the French HTA body be planned? An exhaustive retrospective case-control study of medicinal products appraisals from 2016 to 2021.
    Fernandez J, Babin C, Thomassin C, Pelon F, Kelley S, Cochat P, Galbraith M, Berdaï D, Pariente A, Salvo F, Vanier A.
    Int J Technol Assess Health Care. 2024
  9. Can We Ask ChatGPT About Drug Safety? Appropriateness of ChatGPT Responses to Questions About Drug Use and Adverse Reactions Received by Pharmacovigilance Centers.
    Pariente A, Salvo F, Bres V, Faillie JL.
    Drug Saf. 2024
  10. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
    Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C.
    Drug Saf. 2024
  11. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
    Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C.
    Drug Saf. 2024
  12. Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study).
    Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Devillier P.
    Lancet Reg Health Eur. 2024
  13. Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data.
    Cicala G, Barbieri MA, Russo G, Salvo F, Spina E.
    Pharmaceuticals (Basel). 2024
  14. Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis.
    Raschi E, Salvo F, Bate A, De Ponti F, Poluzzi E, Tuccori M, van Puijenbroek E, Joshi N, Khouri C.
    Drug Saf. 2024
  15. Resective epilepsy surgery and its impact on depression in adults: a systematic review, meta-analysis, and implications for future research.
    Hernandez Poblete N, Gay F, Salvo F, Micoulaud-Franchi JA, Bienvenu T, Coelho J, Aupy J.
    J Neurol Neurosurg Psychiatry. 2024
  16. Hexahydrocannabinol poisoning reported to French poison centres.
    Labadie M, Nardon A, Castaing N, Bragança C, Daveluy A, Gaulier JM, El Balkhi S, Grenouillet M; French Poison Centre Research Group; Christine Tournoud.
    Clin Toxicol (Phila). 2024
  17. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network.
    Gandolfo P, Soeiro T, Jouve É, Revol B, Daveluy A, Bertin C, Eiden C, Gibaja V, Chaouachi L, Pérault-Pochat MC, Chevallier C, Aquizérate A, Le Boisselier R, Carton L, Lapeyre-Mestre M, Frauger É, Lacroix C, Micallef J.
    Fundam Clin Pharmacol. 2024
  18. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
    de Germay S, Pambrun E, Pariente A, Grenet G, Bezin J, Faillie JL.
    Diabetes Obes Metab. 2024
  19. What should be done to combat misinformation about health products?
    Micallef J, Maisonneuve H, Muller S, Molimard M, Bégaud B, Cabut S, Daban M, Drici MD, Gatignol C, Grumblat A, Guaspare-Cartron C, Lasserre B, Mebarki A, Pons C, Prabonnaud F, Raynaud C, Saint-Lary O.
    Therapie. 2023
  20. A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort.
    Devillier P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Demoly P.
    Expert Rev Clin Immunol. 2023